Compare DexCom, Inc. (DXCM) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI United Kingdom (FTSE) — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B). The key difference: DexCom, Inc. is far larger — about 8.8× iShares MSCI United Kingdom (FTSE)'s market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares MSCI United Kingdom (FTSE) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares MSCI United Kingdom (FTSE) for 46 Days on average.
| DXCM | EWU | |
|---|---|---|
Market Cap | $31.86B | $3.62B |
Volume | 3,607,070 | 923,896 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $49.39 |
52-Week Low | $54.84 | $41.34 |
Typical Hold Time | 62 Days | 46 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
EWU trades at $46.23, up 0.65% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is testing key support at $46 amid rising UK gilt yields and inflation concerns. Recent UK housing policy announcements have boosted related sectors, but broader European economic pressures and ECB rate hikes create headwinds for the UK-focused ETF.
The outlook remains cautious given technical weakness and macroeconomic pressures from rising interest rates and energy prices. Investment opportunity exists if housing stimulus gains traction, but risks include prolonged inflation and further ECB tightening that could pressure UK equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
